Japan Approves Insmed's BRINSUPRI for Non-CF Bronchiectasis
INSM sits 39% above its 52-week low of $90.39 on light trading volume (0.3× avg).
Summary
Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib 25-mg) for non-cystic fibrosis bronchiectasis, expanding the drug's reach to a third major market after the U.S. and Europe. The approval is backed by Phase 3 ASPEN data showing significant reduction in pulmonary exacerbations and slower lung function decline. This follows Insmed's Q2 report where BRINSUPRI drove revenue to $425.5M, up 296% YoY, and the company raised full-year guidance. Japan represents a meaningful commercial opportunity for a drug already showing strong launch momentum. Watch for initial Japan sales uptake in upcoming quarters.
At the time of this announcement, INSM was trading at $126.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5B. The 52-week trading range was $90.39 to $212.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: dpa-AFX.